NRx Pharmaceuticals (NASDAQ: NRXP) has announced the appointment of Prof. Joshua C. Brown, MD, PhD, as chief medical officer.
Prof. Brown, a pioneer in understanding the biologic effect of Transcranial Magnetic Stimulation (TMS) and enhancing that biologic effect with neuroplastic medications, is a psychiatrist, neurologist, and neuroscientist. He studies the underlying mechanisms of TMS and translating these mechanisms into clinical optimization. Prof. Brown is the Medical Director of the McLean Hospital TMS Service, the Director of TMS research, and founding director of the Brain Stimulation Mechanisms Laboratory.
In a statement, Jonathan Javitt, MD, MPH, chairman and CEO of NRx, commented, “We are excited to have Dr. Brown bring his extraordinary scientific leadership and clinical acumen to our drug development program and especially to our focus on reversing PTSD and depression in military personnel, veterans, and first responders.”
